Oxaborole Antifungal [EPC]

Oxaborole Antifungal [EPC] was reported 70 times

Drugs of the Oxaborole Antifungal [EPC] class are most commonly taken among patients reporting these side effects:

# Drug class Count Frequency
0 PRIMARY STABBING HEADACHE 1 0.0141
1 ONYCHOMALACIA 1 0.0080
2 APPLICATION SITE HYPOAESTHESIA 1 0.0043
3 RIB DEFORMITY 1 0.0039
4 EAR OPERATION 1 0.0027
5 BODY DYSMORPHIC DISORDER 1 0.0027
6 TEMPOROMANDIBULAR PAIN AND DYSFUNCTION SYNDROME 1 0.0023
7 FUNGAL FOOT INFECTION 1 0.0023
8 SHORT-BOWEL SYNDROME 1 0.0015
9 INFUSION SITE INFLAMMATION 1 0.0014
10 IMMUNISATION REACTION 1 0.0014
11 PRODUCT CONTAINER SEAL ISSUE 2 0.0011
12 PRODUCT OUTER PACKAGING ISSUE 1 0.0011
13 INFUSION SITE DISCOMFORT 1 0.0010
14 NAIL GROWTH ABNORMAL 1 0.0009
15 CHEMICAL BURN 1 0.0009
16 FAT TISSUE INCREASED 1 0.0007
17 APPLICATION SITE DRYNESS 2 0.0006
18 PANCREATIC CYST 1 0.0005
19 INFUSION SITE BRUISING 1 0.0005
20 PRODUCT PACKAGE ASSOCIATED INJURY 1 0.0004
21 INGROWING NAIL 1 0.0004
22 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 1 0.0004
23 ONYCHOCLASIS 2 0.0003
24 SNORING 1 0.0003
25 FUNGAL SKIN INFECTION 1 0.0002
26 APPLICATION SITE EXFOLIATION 1 0.0002
27 INCORRECT DRUG ADMINISTRATION RATE 1 0.0002
28 PRODUCT CONTAINER ISSUE 2 0.0002
29 ONYCHOMYCOSIS 1 0.0002
30 VASCULAR DEVICE INFECTION 1 0.0002
31 GASTROINTESTINAL SOUNDS ABNORMAL 1 0.0002
32 APPLICATION SITE SWELLING 1 0.0002
33 HYPERAMMONAEMIA 1 0.0002
34 PRODUCT DELIVERY MECHANISM ISSUE 1 0.0002
35 BACK INJURY 2 0.0002
36 PRODUCT LEAKAGE 1 0.0002
37 APPETITE DISORDER 1 0.0002
38 PRODUCT DOSE OMISSION IN ERROR 4 0.0001
39 FAECES SOFT 1 0.0001
40 LIQUID PRODUCT PHYSICAL ISSUE 1 0.0001
41 PYELONEPHRITIS 1 0.0001
42 NAIL DISORDER 1 0.0001
43 INJECTION SITE DISCOMFORT 1 0.0001
44 THYROID CANCER 1 0.0001
45 APPLICATION SITE IRRITATION 1 0.0001
46 DERMATITIS ALLERGIC 1 0.0001
47 INJECTION SITE IRRITATION 1 0.0001
48 TACHYPNOEA 1 0.0001
49 SKIN IRRITATION 3 0.0001
50 THYROID DISORDER 1 0.0001
51 THERAPY PARTIAL RESPONDER 1 0.0001
52 PRODUCT USE COMPLAINT 1 0.0001
53 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 1 0.0001
54 GASTROENTERITIS VIRAL 1 0.0001
55 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 1 0.0001
56 INJECTION SITE WARMTH 1 0.0000
57 MOUTH ULCERATION 1 0.0000
58 JOINT INJURY 1 0.0000
59 GLYCOSYLATED HAEMOGLOBIN INCREASED 1 0.0000
60 EXPOSURE VIA SKIN CONTACT 1 0.0000
61 DEAFNESS 1 0.0000
62 APPLICATION SITE ERYTHEMA 1 0.0000
63 DERMATITIS ATOPIC 2 0.0000
64 PAIN OF SKIN 1 0.0000
65 LIMB INJURY 1 0.0000
66 DEVICE DELIVERY SYSTEM ISSUE 1 0.0000
67 INTENTIONAL DOSE OMISSION 1 0.0000
68 BLOOD POTASSIUM DECREASED 1 0.0000
69 LACRIMATION INCREASED 1 0.0000
70 CYSTITIS 1 0.0000
71 CHOLELITHIASIS 1 0.0000
72 EYE PRURITUS 1 0.0000
73 TRANSIENT ISCHAEMIC ATTACK 1 0.0000
74 BLINDNESS 1 0.0000
75 SKIN EXFOLIATION 2 0.0000
76 THERAPY CESSATION 1 0.0000
77 PERIPHERAL SWELLING 3 0.0000
78 ILLNESS 2 0.0000
79 ACCIDENTAL EXPOSURE TO PRODUCT 2 0.0000
80 ECZEMA 1 0.0000
81 INFLUENZA 2 0.0000
82 BLISTER 1 0.0000
83 ASTHMA 2 0.0000
84 FLATULENCE 1 0.0000
85 DYSPHONIA 1 0.0000
86 SURGERY 1 0.0000
87 THERAPEUTIC RESPONSE DECREASED 1 0.0000
88 ALANINE AMINOTRANSFERASE INCREASED 1 0.0000
89 INFUSION RELATED REACTION 1 0.0000
90 INFECTION 2 0.0000
91 INJECTION SITE SWELLING 1 0.0000
92 INJECTION SITE PAIN 4 0.0000
93 ARTHRITIS 1 0.0000
94 INJECTION SITE HAEMORRHAGE 1 0.0000
95 THROMBOSIS 1 0.0000
96 GASTROOESOPHAGEAL REFLUX DISEASE 1 0.0000
97 INTENTIONAL PRODUCT MISUSE 1 0.0000
98 MUSCULOSKELETAL STIFFNESS 1 0.0000
99 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 2 0.0000
100 NO ADVERSE EVENT 2 0.0000
101 ADVERSE EVENT 1 0.0000
102 NASOPHARYNGITIS 2 0.0000
103 HYPERSENSITIVITY 2 0.0000
104 COUGH 3 0.0000
105 PRURITUS 4 0.0000
106 ATRIAL FIBRILLATION 1 0.0000
107 ALOPECIA 2 0.0000
108 DYSPEPSIA 1 0.0000
109 HEART RATE INCREASED 1 0.0000
110 SINUSITIS 1 0.0000
111 SEIZURE 1 0.0000
112 CHILLS 1 0.0000
113 DRUG INEFFECTIVE 11 0.0000
114 JOINT SWELLING 1 0.0000
115 PRODUCT USE IN UNAPPROVED INDICATION 2 0.0000
116 VISUAL IMPAIRMENT 1 0.0000
117 INJECTION SITE ERYTHEMA 1 0.0000
118 HYPERHIDROSIS 1 0.0000
119 DRY SKIN 1 0.0000
120 PRODUCT QUALITY ISSUE 1 0.0000
121 WEIGHT DECREASED 2 0.0000
122 RASH 3 0.0000
123 OFF LABEL USE 6 0.0000
124 PAIN IN EXTREMITY 2 0.0000
125 BLOOD PRESSURE INCREASED 1 0.0000
126 HOSPITALISATION 1 0.0000
127 ABDOMINAL DISCOMFORT 1 0.0000
128 URINARY TRACT INFECTION 1 0.0000
129 COVID-19 1 0.0000
130 MUSCLE SPASMS 1 0.0000
131 GAIT DISTURBANCE 1 0.0000
132 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 1 0.0000
133 DIARRHOEA 3 0.0000
134 MALAISE 2 0.0000
135 INCORRECT DOSE ADMINISTERED 1 0.0000
136 DYSPNOEA 2 0.0000
137 PRODUCT DOSE OMISSION ISSUE 1 0.0000
138 HEADACHE 2 0.0000
139 FALL 1 0.0000
140 FATIGUE 2 0.0000
141 ARTHRALGIA 1 0.0000
142 DEATH 2 0.0000
143 PAIN 1 0.0000
144 NAUSEA 1 0.0000